Filing Flows › Entrada Therapeutics (TRDA) › Q3 2026 › vs Q3 2025
Entrada Therapeutics (TRDA) Q3 2026 vs Q3 2025 (year over year)
Entrada Therapeutics's revenue fell $709K (-44%) from $1.6M in Q3 2025 to $905K in Q3 2026.
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $905K | $1.6M | −$709K | -44% |
| Other income, net | $2.0M | $3.6M | −$1.6M | -45% |
| Net loss | $39.7M | $44.1M | −$4.4M | -10% |
| Costs & expenses | $42.6M | $49.3M | −$6.7M | -14% |
| Operating costs | $42.6M | $48.7M | −$6.1M | -12% |
| Income tax | $27K | $654K | −$627K | -96% |
| Research & development | $32.4M | $38.4M | −$6.0M | -16% |
| General & admin | $10.2M | $10.3M | −$79K | -0.8% |
| Operating cash sources | $39.7M | $44.1M | −$4.4M | -10% |
| Depreciation | $700K | $1.2M | −$500K | -42% |
| Share-based compensation | $4.8M | $5.1M | −$338K | -7% |
| Working capital & other | $4.3M | $9.5M | −$5.2M | -55% |
| Cash used in operations | $30.0M | $28.3M | $1.7M | +6% |
| Net loss absorbed | $39.7M | $44.1M | −$4.4M | -10% |
Questions
How much did Entrada Therapeutics's revenue grow year over year in Q3 2026?
Entrada Therapeutics's revenue fell $709K (-44%) from $1.6M in Q3 2025 to $905K in Q3 2026.